Home Cart Sign in  
Chemical Structure| 1223001-51-1 Chemical Structure| 1223001-51-1

Structure of Torin 2
CAS No.: 1223001-51-1

Chemical Structure| 1223001-51-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Torin 2 is an mTOR inhibitor with an EC50 of 0.25 nM for inhibiting cellular mTOR activity, exhibiting 800-fold selectivity over PI3K (EC50: 200 nM), and also inhibiting DNA-PK with an IC50 of 0.5 nM in a cell-free assay. Torin 2 suppresses both mTORC1 and mTORC2.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Torin 2

CAS No. :1223001-51-1
Formula : C24H15F3N4O
M.W : 432.40
SMILES Code : O=C1N(C2=CC=CC(C(F)(F)F)=C2)C3=C(C=NC4=CC=C(C5=CC=C(N)N=C5)C=C43)C=C1
MDL No. :MFCD18782652
InChI Key :GUXXEUUYCAYESJ-UHFFFAOYSA-N
Pubchem ID :51358113

Safety of Torin 2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Torin 2

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • mTOR

    mTOR, IC50:0.25 nM

  • ATM

    ATM, EC50:28 nM

  • ATR

    ATR, EC50:35 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
NRVMs cells 50 nM 3 h Activated autophagy and increased LC3-II protein levels Autophagy. 2021 Oct;17(10):3124-3139.
HCT-116 100 nM 1 h To evaluate the inhibitory effect of Torin2 on mTORC1 and mTORC2 activity. Cancer Res. 2013 Apr 15;73(8):2574-86.
AG01522 100 nM 24 h To evaluate the sensitivity of Torin2 to IR treatment. Cancer Res. 2013 Apr 15;73(8):2574-86.
HEK293LU cells 50 nM 3 h Activated autophagy and increased the number of GFP-LC3 puncta Autophagy. 2021 Oct;17(10):3124-3139.
TM3 cells 10 μM 12 h Torin 2 treatment increased LC3BII form and reduced intracellular mutant myocilin and p62 accumulation, indicating enhanced autophagic flux. JCI Insight. 2021 Mar 8;6(5):e143359.
Rice ZH11 protoplasts 85 µM 4 h To detect the phosphorylation level of OsS6K1 T464, results showed that the phosphorylation level of OsS6K1 T464 in ZH11 was significantly increased after sucrose treatment, while there was no significant change in nin8. iScience. 2024 Dec 9;28(1):111555.
NIH-3T3 cells 150 nM 24 h Torin inhibits phosphorylation of S6 and 4EBP1, and suppresses expression of GFP in wild type Fgf10 reporters but not in mutant Fgf10 reporters. Cell Rep. 2014 Mar 13;6(5):818-26.
canine MM cells (M1, M5, M2, M3, and Jones) 10 μM to 0.125 nM 72 h To evaluate the cytotoxicity of Torin 2 in combination with trametinib, results showed that the combination significantly reduced cell survival. Mol Cancer Ther. 2020 Nov;19(11):2308-2318.
human cutaneous melanoma cells (WM3311, WM2032, WM853–2, WM858) 10 μM to 0.125 nM 72 h To evaluate the cytotoxicity of Torin 2 in combination with trametinib, results showed that the combination significantly reduced cell survival. Mol Cancer Ther. 2020 Nov;19(11):2308-2318.
bladder cancer cells 500 nM 3, 6, 9, or 24 h Validate the efficacy of Torin 2 in cellular systems, confirming its induction of autophagy and reduction of GPX4 levels Cell Death Dis. 2021 Oct 29;12(11):1028.
HaCaT cells 50 nM 1 h Torin 2 treatment increased TRAIL expression, and this increase remained significant after UVB irradiation. Knockdown of FOXO3a reversed the increase in TRAIL expression induced by Torin 2. Cell Signal. 2018 Dec;52:35-47.
A431 cells 50 nM 1 h In A431 cells, Torin 2 treatment similarly increased UVB-induced apoptosis, and TRAIL knockdown did not reverse this effect. Cell Signal. 2018 Dec;52:35-47.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Tg-MYOCY437H mice Topical ocular administration 100 μM Twice daily for 7 days Torin 2 treatment significantly reduced IOP in Tg-MYOCY437H mice and decreased myocilin and p62 accumulation in mouse TM tissues. JCI Insight. 2021 Mar 8;6(5):e143359.
Mice Inducible mutant Kras lung cancer model Oral 10 mg/kg Once daily for one week To evaluate the inhibitory effect of MK-1775 combined with Torin 2 on KRAS-mutant lung cancer Leukemia. 2015 Jan;29(1):27-37.
Mice KRAS-driven lung cancer model Oral 40 mg/kg Once daily for 4 weeks To evaluate the anti-tumor efficacy of Torin2 alone or in combination with the MEK inhibitor AZD6244 in a KRAS-driven lung cancer model. Cancer Res. 2013 Apr 15;73(8):2574-86.
Mice Canine MM xenograft model Oral 40, 60, and 80 mg/kg Daily administration for several days To evaluate the efficacy and toxicity of Torin 2 in a canine MM xenograft model, results showed that Torin 2 inhibited tumor growth at therapeutic doses but caused weight loss in mice. Mol Cancer Ther. 2020 Nov;19(11):2308-2318.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.13mL

4.63mL

2.31mL

References

 

Historical Records

Categories